Revenue
2021
2022
2023
2024
2025
Abivax S.A. (ABVX)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €4.6M | €12.4M | €4.6M | €4.6M | €12.0M |
| Research & development | €177.8M | €146.5M | €103.2M | €48.3M | €47.8M |
| Operating expenses | €250.6M | €185.4M | €132.0M | €69.4M | €53.4M |
| Operating income | −€246.1M | −€173.0M | −€127.4M | −€64.8M | −€41.4M |
| EBITDAderived | −€245.0M | −€171.9M | −€126.7M | −€64.4M | −€41.1M |
| Net income | −€336.1M | −€176.2M | −€147.7M | −€60.7M | −€42.5M |
| Basic EPSper diluted share | -€4.83 | -€2.80 | -€3.43 | -€3.18 | -€2.75 |
| Diluted EPSper diluted share | -€4.83 | -€2.80 | -€3.43 | -€3.18 | -€2.75 |